Is Tofacitinib effective?

Before initiating treatment with Tofacitinib, patients should be screened for latent tuberculosis infection and closely monitored for signs and symptoms of infection (fungal, viral, bacterial, or mycobacterial) during treatment. Treatment should not be started in the presence of active systemic or local infection and should be interrupted if severe infection occurs.

Tofacitinib targets the inflammation present in rheumatoid arthritis, an autoimmune disease, by inhibiting the janus kinase involved in the inflammatory response pathway. , which is characterized by dysregulation of pro-inflammatory cytokines includingIL7, IL15, IL21, IL6, IFN-α and IFN-β, and by blocking the enzymes, tofacitinib is expected to reduce inflammation and other symptoms of the disease. Tofacitinib can be used to treat children with moderate to severe rheumatoid arthritis, psoriatic arthritis, active polyarticular juvenile idiopathic arthritis (pJIA) or juvenile psoriatic arthritis since the age of two years, and adults with moderate to severe ulcerative colitis and ankylosing spondylitis.

Tofacitinibhas been launched in China and has entered the scope of Class B medical insurance. The common specification is tofacitinib citrate tablets. The price paid by medical insurance is relatively cheap, but the reimbursement ratio is different in different regions, and the price after reimbursement will be different. Overseas, there are also tofacitinib generic drugs produced in other countries. The price of each box produced by a Bangladeshi pharmaceutical factory is around RMB 300 (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs and foreign generic drugs are basically the same, and the prices of different specifications will be different.